Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Key Inclusion Criteria:

- Diagnosed IgAN, with biopsy confirmation within 10 years of screening

- 24-hr proteinuria excretion ≥1.0 g/day or 24-hour uPCR ≥0.75 g/g

- Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2

- Stable angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor
blocker (ARBs) as per protocol specification

Key Exclusion Criteria:

- Have received any immunosuppressive treatment or procedures (including
corticosteroids, oral immunosuppressive agents, B cell or plasma cell targeted
therapies, complement targeted therapies, herbal medicines per protocol, and
tonsillectomy) within a wash-out period per protocol

- Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks of
the start of screening

Other protocol defined Inclusion/Exclusion criteria may apply.